RESEARCH ARTICLE

Trajectories and correlates of opioid prescription receipt among patients experiencing interpersonal violence

Jessica R. Williams¹ *, Ishrat Z. Alam²,3, Shabbar I. Ranapurwala²,3

¹ School of Nursing, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America, ² Department of Epidemiology, Gillings School of Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America, ³ Injury Prevention Research Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America

* jrober65@email.unc.edu

Abstract

Interpersonal violence increases vulnerability to the deleterious effects of opioid use. Increased opioid prescription receipt is a major contributor to the opioid crisis; however, our understanding of prescription patterns and risk factors among those with a history of interpersonal violence remains elusive. This study sought to identify 5-year longitudinal patterns of opioid prescription receipt among patients experiencing interpersonal violence within a large healthcare system and sociodemographic and clinical characteristics associated with prescription patterns. This secondary analysis examined electronic health record data from January 2004–August 2019 for a cohort of patients (N = 1,587) referred for interpersonal violence services. Latent class growth analysis was used to estimate trajectories of opioid prescription receipt over a 5-year period. Standardized differences were calculated to assess variation in sociodemographic and clinical characteristics between classes. Our cohort had a high prevalence of prescription opioid receipt (73.3%) and underlying co-morbidities, including chronic pain (54.6%), substance use disorders (39.0%), and mental health diagnoses (76.9%). Six prescription opioid receipt classes emerged, characterized by probability of any prescription opioid receipt at the start and end of the study period (high, medium, low, never) and change in probability over time (increasing, decreasing, stable). Classes with the highest probability of prescription opioids also had the highest proportions of males, chronic pain diagnoses, substance use disorders, and mental health diagnoses. Black, non-Hispanic and Hispanic patients were more likely to be in low or no prescription opioid receipt classes. These findings highlight the importance of monitoring for synergistic co-morbidities when providing pain management and offering treatment that is trauma-informed, destigmatizing, and integrated into routine care.

Introduction

Prescription and non-prescription opioid use disorder and overdose is a national public health crisis: an estimated 115 people die every day due to opioid overdose [1]. Despite efforts to reduce opioid prescriptions, the number of individuals who receive prescriptions each year...
remains high [2]. Opioid prescription receipt greatly increases a person’s risk for adverse outcomes, particularly when prescribed long-term; approximately 21–29% of individuals prescribed long-term opioid therapy for chronic pain use them non-medically [3] and 8–12% develop an opioid use disorder (OUD) [4, 5]. A better understanding of factors associated with long-term opioid prescription receipt, particularly among high-risk populations, can help facilitate efforts to prevent OUD.

Consistent with other substance use disorder research, evidence shows that rather than a single linear trajectory, opioid use follows multiple trajectories characterized by significant heterogeneity in behaviors [6–9]. Prior research has examined opioid use trajectories among diverse groups of patients including veterans, patients receiving care for HIV, patients enrolled in a Medicaid lock-in program, and individuals receiving treatment for OUD [9–12]. Opioid use trajectories have been shown to vary by amount of use (e.g., low, medium, high) and use patterns over time (e.g., increasing use, decreasing use). Trajectory patterns are associated with numerous factors including demographics, comorbid conditions, substance use history, and social/family conditions. These relationships, however, vary based on the population studied.

One population particularly vulnerable to deleterious effects of opioid use is individuals with a history of interpersonal violence. Experiences of interpersonal violence (e.g., intimate partner violence, sexual assault), have been linked to an increased likelihood of prescription opioid use, [13–15] non-medical prescription opioid use, [13, 14] OUD, [16–18] and heroin use [19]. Opioid prescription receipt has also been found to increase odds of OUD in this population. A recent study found that among individuals with a history of interpersonal violence, people who had received an opioid prescription in the past year had a four times greater odds of reporting opioid misuse behaviors compared to those without an opioid prescription [20].

Evidence also suggests that interpersonal violence may influence opioid use trajectories: two studies showed that physical, sexual, and emotional abuse history influences recovery trajectories for individuals seeking treatment for substance use disorders (including OUD), with higher abuse levels predicting more severe psychiatric and social problems and slower recovery times [9, 21]. Although providing some evidence about the role of interpersonal violence in opioid use trajectories, these studies were conducted after treatment for a diagnosed substance use disorder and did not differentiate by type of substance. Thus, our understanding of prescription opioid use patterns among individuals with a history of interpersonal violence remains elusive. Identifying distinct patterns of prescription opioid use among survivors of interpersonal violence and associated characteristics will help us understand who is at risk for escalating opioid use and OUD and provide potential targets for future interventions.

The purpose of this study was to examine longitudinal trajectories of prescription opioid use among patients experiencing interpersonal violence. Specifically, we aimed to:

**Aim 1.** Classify 5-year longitudinal patterns of opioid prescription receipt among patients experiencing interpersonal violence.

**Aim 2.** Identify sociodemographic and clinical characteristics associated with opioid prescription receipt patterns among survivors of interpersonal violence.

**Methods**

**Design**

We conducted a secondary analysis of electronic health record (EHR) data available from January 2004–August 2019 for a cohort of patients referred for interpersonal violence services.
between December 2009–June 2019 at the University of North Carolina (UNC) Health System (N = 1,587). We used latent class growth analysis (LCGA) to estimate trajectories of opioid prescription receipt over a 5-year period. We then examined associations between trajectory patterns and sociodemographic and clinical characteristics. This study was approved by the University of North Carolina Institutional Review Board (#20–0988).

**Study population**

The study population consisted of all adult patients (≥ 18 years of age at baseline) referred to the UNC Hospitals Beacon Program for interpersonal violence services between December 2009–June 2019 with at least one year of data in the EHR during the study period. The Beacon Program provides comprehensive, coordinated care to UNC Health System patients, families, and employees experiencing a interpersonal violence, including intimate partner violence, human trafficking, sexual assault, and elder/vulnerable adult abuse. Individuals were excluded if they had evidence of an OUD at baseline (diagnosis or buprenorphine, methadone, or nal-trexone prescription), had a cancer diagnosis, or were receiving end-of-life care during the study period as opioid prescribing practices differ for these conditions.

**Variables**

All data analyzed in this study were electronically abstracted from the UNC Health System EHR databases. This included data related to opioid prescription receipt and sociodemographic and clinical characteristics. Given that experiences of interpersonal violence are often chronic rather than an isolated event, we did not limit data extraction based on date of referral to the Beacon Program, but rather extracted relevant variables across the study period (January 2004–August 2019).

**Opioid prescription receipt.** We examined prescription drug records for opioid medications prescribed during the study period. Then, we recorded all opioid prescriptions during the 60 months following baseline. We focused on the following opioids commonly prescribed for pain: butorphanol, codeine, dihydrocodeine, fentanyl, hydrocodone, hydromorphone, levorphanol, meperidine, morphine, opium, oxycodone, oxymorphone, pentazocine, propoxyphene, tapentadol, and tramadol. Dosage and duration information was not readily available from the EHR data, especially prior to April 2014; thus, we could not calculate morphine milligram equivalents for prescriptions. Therefore, outcome variable was defined as a binary indicator of any prescription opioid receipt for each month of the study period.

**Socio-demographic and clinical characteristics.** Demographic characteristics were assessed at the beginning of the study period and included age, race, ethnicity, and sex. We examined insurance status across the study period, categorizing patients as insured, not insured, or varying status. We used International Classification of Diseases 9th and 10th edition (ICD-9 and ICD-10) codes to identify medical diagnoses during the study period. Diagnoses included chronic pain conditions, substance use disorders, and mental health conditions. We calculated the Charlson comorbidity index, a method of categorizing comorbidities based on ICD codes, for each patient [22, 23]. Lastly, we collected information on social history, namely, smoking and illicit drug use history. Social history is routinely screened for by providers within the UNC Health System and documented within each patient’s EHR. Specific information on diagnostic codes used to define characteristics is presented in S1 Table.

**Statistical analyses**

LCGA was used to examine opioid prescription receipt over a 5-year time period and identify groups with similar trajectories (Aim 1). Baseline was defined as date of first opioid
prescription during the study period (January 2004–August 2019). Those who did not have an opioid prescription during the study period were placed in a “Never” class. We fit models with 2 to 7 groups to determine the optimal number of trajectories. Model selection was based on a combination of model fit, adequacy, and interpretability. We assessed fit using Akaike’s information criterion (AIC), [24] Bayesian information criterion (BIC), [25] bootstrap likelihood ratio test (BLRT), and entropy. The LCQA was fitted using MPlus, version 8.4.

To estimate the association between sociodemographic and clinical characteristics with trajectory groups, we estimated the prevalence of patient characteristics within each latent class. The analysis was weighted using patient’s posterior probabilities for belonging to a given class. We estimated and graphed standardized differences to assess the degree of similarity and dissimilarity between classes within a given covariate (“Never” class used as reference group). The analysis was conducted in Stata SE, version 6.1.

**Results**

**Baseline population characteristics**

Between December 2009 and June 2019, 4,296 individuals were referred to the Beacon Program for interpersonal violence services. We excluded 2,709 people resulting in a final sample size of 1,587. The primary reason for exclusion was < 1 year of data in the EHR. Cohort characteristics are presented in Table 1. Our cohort was largely female (87.5%), White, non-Hispanic (55.2%) or Black, non-Hispanic (29.3%), insured (77.3%), and had a mean age of 41.4 years (SD = 16.3). Over half (58.3%) had a current smoking history and almost half (44.8%) had a lifetime history of illicit drug use. Our cohort exhibited a high prevalence of chronic pain (54.6%), substance use disorders (39.0%), and mental health diagnoses (76.9%) during the study period. The most common chronic pain diagnoses were chronic low back pain (33.5%) and chronic pain, not elsewhere classified (30.0%). Alcohol (18.0%) and cannabis (16.1%) related disorders were the most prevalent substance use diagnoses; however, rates were similar across all drug related diagnoses. Notably, 13.0% received an OUD diagnosis after baseline (participants were excluded if OUD diagnosis was present at baseline). The most common mental health related diagnoses included depression (65.5%) and anxiety related disorders (53.9%). The mean Charlson comorbidity index was 1.4 (SD = 2.1), which corresponds to an estimated 10-year survival of 94% [23, 26].

**Longitudinal patterns of opioid prescription receipt among patients experiencing interpersonal violence**

Table 2 shows the model fitting results for the LGCA. Four-hundred-twenty-three patients (26.7%) did not receive an opioid prescription during the study period and, thus, were not included in the LGCA. Fit indices favored solutions with an increasing number of classes. The BLRT behaved similarly, yielding significant test results comparing a $K$-class model relative to a $K-1$-class model with an increasing number of classes before becoming unstable at a 7-class solution. We selected a 6-class model for further analyses based on fit indices, interpretability, class size, and stability.

Fig 1 shows trajectories of opioid prescription receipt based on estimated probability over time. We characterized the trajectory classes based on beginning probability, ending probability, and degree of change as follows:

- Never: no opioid prescription receipt (26.7%)
- Class 1: Start medium, end medium, moderate decrease (4.8%)
| Characteristics of study participants, and by latent class of prescription opioid trajectories: Dec 2009- Jun 2019. | Total cohort who received Beacon program assistance (n = 1,587) | Never prescribed opioids (n = 423, 26.7%) | Opioid prescription receipt trajectories developed using LCGA analysis |
|---|---|---|---|
| | Class 1 | Class 2 | Class 3 | Class 4 | Class 5 | Class 6 |
| Start medium, end medium, moderate decrease (n = 75.4, 4.8%) | Start high, end high, slight increase (n = 206.2, 13.0%) | Start medium, end low, sharp decrease (n = 216.6, 13.6%) | Start low, end high, sharp increase (n = 51.1, 3.2%) | Start low, end medium, moderate increase (n = 582.3, 36.7%) | Start low, end low, stable (n = 582.3, 36.7%) |
| Start medium, end medium, moderate decrease (n = 75.4, 4.8%) | Start high, end high, slight increase (n = 206.2, 13.0%) | Start medium, end low, sharp decrease (n = 216.6, 13.6%) | Start low, end high, sharp increase (n = 51.1, 3.2%) | Start low, end medium, moderate increase (n = 582.3, 36.7%) | Start low, end low, stable (n = 582.3, 36.7%) |
| Age (mean, SD) | 41.4 (16.3) | 39.4 (17.4) | 43.4 (14.9) | 47.3 (15.5) | 42.5 (14.9) | 41.9 (15.5) | 40.7 (15.6) | 40.7 (15.6) | 42.0 (16.4) |
| Sex | Male | 198 (12.5) | 51 (12.1) | 15.2 (20.1) | 4.4 (13.7) | 20.3 (9.8) | 7.1 (14.0) | 27.8 (12.9) | 72.2 (12.4) |
| | Female | 1,389 (87.5) | 372 (87.9) | 60.2 (79.9) | 27.9 (86.3) | 185.9 (90.2) | 44.0 (86.1) | 188.7 (87.2) | 510.2 (87.6) |
| Race/Ethnicity | White, non-Hispanic | 847 (55.2) | 210 (52.6) | 84.8 (64.0) | 23.4 (72.2) | 119.4 (59.2) | 29.2 (60.0) | 116.7 (55.2) | 302.0 (53.0) |
| | Black, non-Hispanic | 449 (29.3) | 101 (25.3) | 20.6 (27.4) | 7.9 (24.5) | 62.3 (30.9) | 13.5 (27.8) | 69.8 (33.0) | 173.9 (30.7) |
| | Hispanic | 163 (10.6) | 61 (15.3) | 5.9 (7.9) | 1.0 (3.1) | 12.4 (6.2) | 3.4 (7.0) | 15.0 (7.1) | 64.3 (11.4) |
| | Other, non-Hispanic | 76 (5.0) | 27 (6.8) | 0.5 (0.7) | 0.6 (0.2) | 7.6 (3.8) | 2.6 (5.3) | 10.1 (4.8) | 28.2 (5.0) |
| Insurance | Insured | 1,150 (77.3) | 301 (78.6) | 58.9 (80.7) | 25.7 (80.3) | 152.0 (77.8) | 37.0 (76.3) | 156.7 (76.4) | 418.6 (76.1) |
| | Not insured | 166 (11.2) | 39 (10.2) | 5.6 (7.7) | 1.1 (3.5) | 21.5 (11.0) | 4.1 (8.5) | 22.7 (11.1) | 72.0 (13.1) |
| | Varying | 171 (11.5) | 43 (11.2) | 8.5 (11.6) | 5.2 (16.2) | 22.0 (11.3) | 7.3 (15.1) | 25.7 (12.5) | 59.3 (10.8) |
| Smoking History | Never | 347 (21.9) | 129 (30.6) | 8.4 (11.2) | 6.3 (19.4) | 35.6 (17.3) | 6.5 (12.8) | 37.1 (17.1) | 124.1 (21.3) |
| | Now | 923 (58.3) | 212 (50.4) | 49.6 (66.0) | 19.8 (61.2) | 134.0 (65.2) | 29.2 (57.2) | 136.6 (63.1) | 341.8 (58.7) |
| | Past | 314 (19.8) | 80 (19.0) | 17.1 (22.8) | 6.3 (19.4) | 36.0 (17.5) | 15.4 (30.1) | 42.8 (19.8) | 116.4 (20.0) |
| Illicit Drug—Ever | 707 (44.8) | 186 (44.3) | 36.0 (48.6) | 15.1 (46.7) | 83.4 (40.6) | 23.6 (46.3) | 109.0 (50.4) | 253.9 (43.7) |
| Chronic pain | Chronic Pain, not elsewhere classified | 476 (30.0) | 37 (8.8) | 59.2 (78.5) | 28.5 (88.1) | 95.6 (46.3) | 32.9 (64.4) | 87.9 (40.6) | 135.0 (23.2) |
| | Chronic pain syndrome | 138 (8.7) | 5 (1.2) | 26.6 (35.3) | 13.3 (41.1) | 24.8 (12.0) | 19.7 (38.6) | 24.1 (11.1) | 24.4 (4.2) |
| | Fibromyalgia | 202 (12.7) | 15 (3.6) | 21.2 (28.1) | 10.8 (33.5) | 35.4 (17.2) | 10.2 (20.0) | 41.4 (19.1) | 68.1 (11.7) |
| | Irritable Bowel Syndrome | 58 (3.7) | 4 (1.0) | 7.2 (9.5) | 2.0 (6.2) | 13.5 (6.5) | 3.4 (6.6) | 9.6 (4.4) | 18.4 (3.2) |
| | Interstitial cystitis/Bladder pain syndrome | 15 (1.0) | 0 (0.0) | 1.1 (1.4) | 1.0 (3.1) | 2.4 (1.2) | 1.2 (2.0) | 5.4 (2.5) | 4.1 (0.7) |
| | Migraine | 249 (15.7) | 33 (7.8) | 24.3 (32.3) | 8.1 (25.1) | 40.8 (19.8) | 10.6 (20.8) | 47.5 (21.9) | 84.6 (14.5) |
| | Chronic low back pain | 532 (33.5) | 63 (14.9) | 45.3 (60.1) | 22.0 (68.0) | 90.5 (43.9) | 27.6 (53.9) | 103.5 (47.8) | 180.1 (30.9) |
| | Chronic Fatigue Syndrome | 28 (1.8) | 2 (0.5) | 2.1 (2.8) | 0.0 (0.0) | 3.2 (1.6) | 3.8 (7.5) | 4.9 (2.3) | 12.0 (2.1) |
| | Endometriosis | 45 (2.8) | 1 (0.2) | 3.1 (4.1) | 2.0 (6.2) | 9.0 (4.4) | 5.6 (11.0) | 12.6 (5.8) | 11.7 (2.0) |

(Continued)
Table 1. (Continued)

| Total cohort who received Beacon program assistance (n = 1,587)\(^a\) | Never prescribed opioids (n = 423.0, 26.7%)\(^a\) | Opioid prescription receipt trajectories developed using LCGA analysis |
|---|---|---|
| | | Class 1 | Class 2 | Class 3 | Class 4 | Class 5 | Class 6 |
| | Start medium, end medium, moderate decrease (n = 75.4, 4.8%)\(^b\) | Start high, end high, slight increase (n = 32.4, 2.0%)\(^b\) | Start medium, end low, sharp decrease (n = 206.2, 13.0%)\(^b\) | Start low, end high, sharp increase (n = 51.1, 3.2%)\(^b\) | Start low, end medium, moderate increase (n = 216.6, 13.6%)\(^b\) | Start low, end low, stable (n = 582.3, 36.7%)\(^b\) |
| Sedative, hypnotic, or anxiolytic related disorders | 113 (7.1) | 17 (4.0) | 11.5 (15.2) | 2.0 (6.2) | 22.7 (11.0) | 9.2 (18.1) | 16.5 (7.6) | 34.1 (5.9) |
| Cocaine related disorders | 229 (14.4) | 35 (8.3) | 16.3 (21.7) | 7.4 (22.9) | 39.4 (19.1) | 8.1 (15.9) | 42.1 (19.4) | 80.6 (13.8) |
| Other psychoactive substance related disorders | 209 (13.2) | 47 (11.1) | 15.0 (19.9) | 7.2 (22.2) | 35.2 (17.1) | 11.2 (21.9) | 28.5 (13.2) | 64.9 (11.2) |
| Unspecified/other drug dependence | 178 (11.2) | 18 (4.3) | 17.2 (22.8) | 5.6 (17.4) | 32.6 (15.8) | 9.3 (18.3) | 35.8 (16.6) | 59.4 (10.2) |

Mental health

| | | | | | | | |
| Sedative, hypnotic, or anxiolytic related disorders | 113 (7.1) | 17 (4.0) | 11.5 (15.2) | 2.0 (6.2) | 22.7 (11.0) | 9.2 (18.1) | 16.5 (7.6) | 34.1 (5.9) |
| Cocaine related disorders | 229 (14.4) | 35 (8.3) | 16.3 (21.7) | 7.4 (22.9) | 39.4 (19.1) | 8.1 (15.9) | 42.1 (19.4) | 80.6 (13.8) |
| Other psychoactive substance related disorders | 209 (13.2) | 47 (11.1) | 15.0 (19.9) | 7.2 (22.2) | 35.2 (17.1) | 11.2 (21.9) | 28.5 (13.2) | 64.9 (11.2) |
| Unspecified/other drug dependence | 178 (11.2) | 18 (4.3) | 17.2 (22.8) | 5.6 (17.4) | 32.6 (15.8) | 9.3 (18.3) | 35.8 (16.6) | 59.4 (10.2) |

\(^a\)Counts, percentages, and means are unweighted.
\(^b\)Counts, percentages, and means are weighted by patient’s posterior probabilities for belonging to a given class.

SD = standard deviation.

Table 2. Model fit statistics (n = 1,164).

| Number of Classes | AIC | BIC | Adjusted BIC | BLRT Test Statistic | p value | Entropy |
|---|---|---|---|---|---|---|
| 1 Class | 31860.484 | 31870.603 | 31864.251 | - | - | - |
| 2 Class | 26787.922 | 26813.220 | 26797.339 | 5078.562 | 0.0000 | 0.931 |
| 3 Class | 25646.498 | 25686.975 | 25661.565 | 1147.424 | 0.0000 | 0.889 |
| 4 Class | 25176.558 | 25232.213 | 25197.274 | 475.941 | 0.0000 | 0.811 |
| 5 Class | 24885.560 | 24956.395 | 24911.926 | 296.997 | 0.0000 | 0.758 |
| 6 Class | 24689.233 | 24775.247 | 24721.249 | 202.327 | 0.0000 | 0.738 |
| 7 Class | 24585.536 | 24686.728 | 24623.201 | 109.698 | 0.0000 | 0.757 |

Note. AIC = Akaike information criteria; BIC = Bayesian information criteria; BLRT = Bootstrap Likelihood Ratio Test.
• Class 2: Start high, end high, slight increase (2.0%)
• Class 3: Start medium, end low, sharp decrease (13.0%)
• Class 4: Start low, end high, sharp increase (3.2%)
• Class 5: Start low, end medium, moderate increase (13.6%)
• Class 6: Start low, end low, stable (36.7%)

Most participants clustered around patterns indicative of no or minimal opioid prescription probability (63.4%, Never and Class 6). The remaining classes, which characterize higher probabilities of opioid prescription receipt, demonstrated considerable variability over time. The two classes that began with a medium probability (Class 1 and Class 3), both showed decreases over time. The only class that began with a high probability (Class 2), remained high over time and slightly increased. Two classes that started low (Class 4 and 5), demonstrated increases over time.

Sociodemographic and clinical characteristics associated with opioid prescription receipt trajectories

A number of sociodemographic and clinical characteristics were associated with opioid prescription receipt trajectories (Table 1, Fig 2). A summary of the key characteristics for each trajectory group is provided in S2 Table. Overall, prescription opioid classes (Classes 1–6) demonstrated higher prevalence for smoking, chronic pain, substance use disorders, mental
health disorders, and Charlson comorbidity index compared with the Never class. Never class were also the youngest among all classes. Class 6 (start low, end low) was most like the Never class, demonstrating the smallest standardized mean differences. The largest proportion of White, non-Hispanic patients was seen in the classes with the highest probability of prescription opioids (Class 1, 2, and 4). Males were also more likely to be represented in these classes whereas the highest proportion of females were in Class 3 (start medium, end low, sharp decrease). Black, non-Hispanic patients were more likely to be in low prescription opioid classes (Class 3, 5, and 6) and Hispanic and Other, non-Hispanic patients in the Never class. The largest proportion of insured patients were seen in higher prescription opioid classes (Class 1 and 2). Those with varying insurance status were also more likely to be represented in high prescription opioid classes (Class 2 and 4). Classes 1, 2, and 4, which demonstrated the highest probabilities of opioid use, had the highest proportions of chronic pain diagnoses, substance use disorders, including OUD, and mental health diagnoses.

Comparison of Class 4 and Class 5. Individuals who clustered around Class 4 and Class 5 both started with a low probability of opioid prescription; however, Class 4 demonstrated a sharp increase in the probability of opioid prescription over time whereas Class 5 demonstrated a more moderate increase. We compared these two classes to identify factors that may contribute to the increased opioid prescription trajectory for Class 4. Both classes had similar demographics except Class 5 had a higher proportion of Black, non-Hispanics. Class 4 had a higher prevalence of chronic pain diagnoses (except for interstitial cystitis/bladder pain syndrome and migraine) and mental health disorders. Class 4 also had a higher prevalence of substance use disorders.

Comparison of Class 1 and Class 3. Class 1 and Class 3 both started with a medium probability of prescription opioid use; Class 3 demonstrated a sharp decline over time and Class 1 demonstrated a more moderate decrease. We compared these two classes to identify factors that may contribute to the sharper decline in opioid prescription trajectory for Class 3. Both classes had similar demographics except Class 3 had a higher proportion of females. Class 3 had a lower prevalence of most pain diagnoses (except endometriosis and interstitial cystitis/bladder pain syndrome), substance use disorders, and mental health diagnoses compared to Class 1.

Discussion
This study is the first to examine longitudinal prescription opioid trajectories among a cohort of patients with a history of interpersonal violence. Almost three-quarters (73.3%) received an opioid prescription during the study period (January 2004–August 2019). We identified six distinct patterns of opioid prescriptions over time, varying by starting and ending probability (high, medium, low, never) and degree of change over time (increase, decrease, stable). These findings indicate significant heterogeneity in opioid prescriptions over time among those impacted by interpersonal violence. This heterogeneity echoes findings from prior research that have modelled opioid use trajectories among other high-risk populations and provides further evidence of the presence of clinically significant subgroups of people who use prescription opioids [9–12].

Sociodemographic and clinical characteristics varied by prescription opioid trajectory class. Males were more likely to be represented in classes with the highest probability of being prescribed opioids (Class 1, 2, & 4) and the highest proportion of females was seen in Class 3 (start medium, end low, sharp decrease). These findings are consistent with prior research showing that women are more likely to be prescribed and use lower doses of opioids compared to men; [27] however, contrast with other studies indicating that women, in general, are more
likely to be prescribed opioids [28–31]. The higher proportion of males in the higher prescription opioid use classes may be problematic given that prior research indicates that men are at higher risk of misusing opioids [31–33]. The potential role of interpersonal violence on these differences is unclear. Only one study has examined sex differences in prescription opioid use among individuals with a history of interpersonal violence and did not find significant differences between males and females [34]. Additional work is needed to understand better sex differences in the relationship between interpersonal violence and prescription opioid use.
Race was also associated with class membership in our study. Specifically, Black, non-Hispanic patients were more likely to be in low prescription opioid classes (Class 3, 5, and 6) and Hispanic and Other, non-Hispanic patients in the Never class. This is consistent with the abundance of research highlighting racial/ethnic disparities in opioid prescribing practices through the U.S. [35–38]. Specifically, individuals of racial/ethnic minority statues are less likely than Whites to be prescribed opioids for pain and more likely to have pain symptoms underestimated by providers [35–38]. These disparities in pain management can be attributed to mistrust and biases by providers; [39, 40] negative experiences that often influence a patient’s engagement in healthcare services, quality of patient-provider communication, and health outcomes [41–44]. These consequences may be exacerbated in patients with a history of interpersonal violence, which has also been shown to lead to discomfort, perceived discrimination, stigma, and mistrust in the healthcare environment [45–47]. Additional research is needed to understand better the intersection of interpersonal violence and racial/ethnic bias on the pain experience and to develop evidence-based approaches to mitigate their effects on pain management.

There was high prevalence of underlying co-morbidities within our cohort including chronic pain (54.6%), substance use disorders (39.0%), and mental health diagnoses (76.9%). The classes with the highest probability of prescription opioids (Classes 1, 2, and 4) also had the highest proportions of chronic pain diagnoses, substance use disorders, and mental health diagnoses. These co-morbidities also appeared to contribute to escalating risk of opioid use over time when comparing Class 4 to Class 5 and Class 1 to Class 3. Our findings also echo prior literature indicating that long-term prescription opioid use increases risk for OUD, both in the general population and among those with a history of IPV [3, 20]. In our cohort, 13.0% received an OUD diagnosis after baseline and this proportion was markedly higher among classes with higher probability of prescription opioid receipt over time (e.g., Class 4 = 31.9%; Class 2 = 28.2%; Class 1 = 23.3%). Prior research estimates that, in the general population, about 8–12% of people who are prescribed opioids will develop an OUD [3–5]. While we are unable to determine if the increased rates of OUD in our study are a result of new OUD cases or increased monitoring/identification, our findings provide some preliminary evidence that IPV may increase risk for the development of OUD among those prescribed opioids. Additional research is needed to better understand this potential risk.

The high rates of co-morbidities found in this study, especially among classes with higher probability of prescription opioid receipt over time, is consistent with the abundance of research demonstrating that chronic pain, substance use, and mental health conditions are common consequences of interpersonal violence [48–51]. More recently, researchers have begun to establish that these consequences are not independent of each other, but rather interact synergistically (often referred to as syndemic health conditions [52]), resulting in worsening health [20, 50, 53, 54]. Given this, it may be particularly important to monitor for synergistic co-morbidities when providing pain management and offer treatment that is trauma-informed, destigmatizing, and integrated into routine care.

A major limitation, however, in providing effective pain management for patients impacted by interpersonal violence is a lack of trauma-informed pain management strategies. Trauma-informed care provides a model to assist health providers understand, recognize, and respond to the effects of trauma on patients’ health [55]. Interventions based on a trauma-informed approach have shown promise for improving patient outcomes in a variety of settings; [56–62] however, limited evidence exists on the impact of trauma-informed care on pain-related outcomes. Additional research is needed to examine how current evidence-based pain management practices can be tailored to better address the specific challenges (e.g., comorbid conditions) survivors of interpersonal violence face during their path to recovery.
Limitations

There are several limitations, which should be acknowledged. 1) Our sample was limited to UNC Health Care System patients identified as experiencing interpersonal violence and referred for services. This misses those who may be experiencing interpersonal violence but were not identified or referred, thus reducing our generalizability. In addition, our study was conducted in one health care system in North Carolina, which also impacts generalizability. 2) Given the secondary nature of our data, we were not be able to determine the frequency, duration, or severity of interpersonal violence, which has been shown in prior work to impact opioid use [34]. 3) We were only able to examine longitudinal trends in opioid prescription receipt, and unable to examine trends in prescription dosage among people affected by interpersonal violence. This is important because prior studies show that higher doses and longer durations of opioid receipt are associated with OUD and overdose. Our study findings suggest that people with exposure to interpersonal violence are at high risk for both opioid use and OUD and may, therefore, be an important factor to consider when prescribing opioids. However, without information on morphine milligrams equivalent or days’ supply, it is difficult to identify those who may specifically benefit from an opioid prescribing-related intervention. 4) Lastly, we examine the probabilities of receiving an opioid prescription for pain management, which may overestimate the people who actually fill and consume those prescription opioids. However, given the high prevalence of pain, substance use disorders, mental health disorders, and Charlson morbidity index among those receiving opioid prescriptions in this study, it is feasible to expect that vast majority of these prescriptions may have been filled and consumed.

Conclusions

Results from this exploratory study suggest that people with exposure to interpersonal violence are at high risk for prescription opioid use (>70%) and OUD (13%). The different trajectories may help target interventions to people with interpersonal violence exposure who are at the highest risk for OUD (trajectories 1, 2, and 4). The high rates of co-morbid conditions among trajectories with higher probability of prescription opioid receipt over time highlight the importance of monitoring for co-morbidities among patients receiving care for chronic pain and the need for improved trauma-informed pain management strategies.

Supporting information

S1 Table. International classification of diseases 9th and 10th edition (ICD-9, ICD-10) codes used to define model covariates. (DOCX)

S2 Table. Summary of key characteristics for each opioid prescription trajectory class. (DOCX)

Acknowledgments

The authors acknowledge the support of Bill Ross and the NC Translational and Clinical Science (NC TraCS) Institute in assisting with data extraction from the UNC Health Care System electronic health records. NC TraCS is supported by the National Center for Advancing Translational Science (NCATS), National Institutes of Health, through Grant Award Number UL1TR002489.
Author Contributions

Conceptualization: Jessica R. Williams, Shabbar I. Ranapurwala.

Data curation: Ishrat Z. Alam.

Formal analysis: Ishrat Z. Alam.

Funding acquisition: Jessica R. Williams.

Methodology: Jessica R. Williams, Shabbar I. Ranapurwala.

Project administration: Jessica R. Williams.

Supervision: Jessica R. Williams.

Writing – original draft: Jessica R. Williams, Ishrat Z. Alam.

Writing – review & editing: Jessica R. Williams, Ishrat Z. Alam, Shabbar I. Ranapurwala.

References

1. Centers for Disease Control and Prevention, National Center for Health Statistics. Mortality. CDC Wonder. Atlanta, GA: US Department of Health and Human Services, CDC; 2018 [https://wonder.cdc.gov.

2. Centers for Disease Control and Prevention. 2019 Annual Surveillance Report of Drug-Related Risks and Outcomes—United States Surveillance Special Report. 2019 https://cdc.gov/drugoverdose/pdf/pubs/2019-cdc-drug-surveillance-report.pdf.

3. Vowles KE, McEntee ML, Julnes PS, Frohe T, Nay JP, van der Goes DN. Rates of opioid misuse, abuse, and addiction in chronic pain: A systematic review and data synthesis. Pain. 2015; 156(4):569–76. https://doi.org/10.1097/01.j.pain.0000460357.01998.f1 PMID: 25785523

4. Cicero TJ, Ellis MS, Surratt HL, Kurtz SP. The changing face of heroin use in the United States: A retrospective analysis of the past 50 years. JAMA Psychiatry. 2014; 71(7):821–6. https://doi.org/10.1001/jamapsychiatry.2014.366 PMID: 24871348

5. Carlson RG, Nahhas RW, Martins SS, Danilaityte R. Predictors of transition to heroin use among initially non-opioid dependent illicit pharmaceutical opioid users: A natural history study. Drug Alcohol Depend. 2016; 160:127–34. https://doi.org/10.1016/j.drugalcdep.2015.12.026 PMID: 26785634

6. Hser YI, Longshore D, Anglin MD. The life course perspective on drug use: A conceptual framework for understanding drug use trajectories. Eval Rev. 2007; 31(6):515–47. https://doi.org/10.1177/0193841X07307316 PMID: 17986706

7. Hser YI, Evans E, Grella C, Ling W, Anglin D. Long-term course of opioid addiction. Harv Rev Psychiatry. 2015; 23(2):76–89. https://doi.org/10.1097/HRP.000000000000052 PMID: 25747921

8. Hser YI, Huang D, Saxon AJ, Woody G, Moskowitz AL, Matthews AG, et al. Distinctive trajectories of opioid use over an extended follow-up of patients in a multisite trial on buprenorphine + naloxone and methadone. J Addict Med. 2017; 11(1):63–9. https://doi.org/10.1097/ADM.0000000000000274 PMID: 27898496

9. Lopez-Castro T, Hu MC, Papini S, Ruglass LM, Hien DA. Pathways to change: Use trajectories following trauma-informed treatment of women with co-occurring post-traumatic stress disorder and substance use disorders. Drug and alcohol review. 2015; 34(3):242–51. https://doi.org/10.1111/dar.12230 PMID: 25735200

10. Rentsch CT, Edelman EJ, Justice AC, Marshall BDL, Xu K, Smith AH, et al. Patterns and Correlates of Prescription Opioid Receipt Among US Veterans: A National, 18-Year Observational Cohort Study. AIDS and behavior. 2019; 23(12):3340–9. https://doi.org/10.1007/s10461-019-02608-3 PMID: 31317364

11. Brunet L, Napravnik S, Heine AD, Leone PA, Eron JJ. Brief report: Longitudinal opioid use among HIV-infected patients, 2000 to 2014. J Acquir Immune Defic Syndr. 2017; 75(1):77–80. https://doi.org/10.1097/QAI.0000000000001321 PMID: 28198711

12. Naumann RB, Marshall SW, Gottfredson NC, Lund JL, Ringwalt CL, Skinner AC. Trajectories of dispensed prescription opioids among beneficiaries enrolled in a Medicaid controlled substance “lock-in” program. Pharmacoeconomics Drug Saf. 2019; 28(1):16–24. https://doi.org/10.1002/pds.4445 PMID: 29700904
13. Stene LE, Dyb G, Tverdal A, Jacobsen GW, Schei B. Intimate partner violence and prescription of potentially addictive drugs: Prospective cohort study of women in the Oslo Health Study. BMJ Open. 2012; 2(2):e000614. https://doi.org/10.1136/bmjopen-2011-000614 PMID: 22492384

14. Young A, Grey M, Boyd CJ, McCabe SE. Adolescent Sexual Assault and the Medical and Nonmedical Use of Prescription Medication. J Addict Nurs. 2011; 11(1–2):25–31. https://doi.org/10.3109/1088461036838840 PMID: 22065397

15. Wuest J, Merritt-Gray M, Lent B, Varcoe C, Conners AJ, Ford-Gilboe M. Patterns of medication use among women survivors of intimate partner violence. Can J Public Health. 2007; 98(6):460–4. https://doi.org/10.1007/BF03405439 PMID: 19039883

16. Smith PH, Homish GG, Leonard KE, Corneliaus JR. Intimate partner violence and specific substance use disorders: findings from the National Epidemiologic Survey on Alcohol and Related Conditions. Psychol Addict Behav. 2012; 26(2):236–45. https://doi.org/10.1037/a0024855 PMID: 21823768

17. Walsh K, Keyes KM, Koenen KC, Hasin D. Lifetime prevalence of gender-based violence in US women: Associations with mood/anxiety and substance use disorders. Journal of Psychiatric Research. 2015; 62:7–13. https://doi.org/10.1016/j.jpsychires.2015.01.002 PMID: 25648384

18. Garami J, Valikhani A, Parkes D, Haber P, Mahlberg J, Misiak B, et al. Examining Perceived Stress, Childhood Trauma and Interspersonal Trauma in Individuals With Drug Addiction. Psychol Rep. 2019; 122(2):433–50. https://doi.org/10.1177/0033294118764918 PMID: 29569991

19. El-Bassel N, Gilbert L, Wu E, Go H, Hill J. Relationship between drug abuse and intimate partner violence: a longitudinal study among women receiving methadone. Am J Public Health. 2005; 95(3):465–70. https://doi.org/10.2105/AJPH.2003.023200 PMID: 15727978

20. Williams JR, Cole V, Girdler S, Cromeens MG. Exploring stress, cognitive, and affective mechanisms of the relationship between interpersonal trauma and opioid misuse. PLOS One. 2020; 15(5):e0233185. https://doi.org/10.1371/journal.pone.0233185 PMID: 32413081

21. Branstetter SA, Bower EH, Kamien J, Amass L. A history of sexual, emotional, or physical abuse predicts adjustment during opioid maintenance treatment. J Subst Abuse Treat. 2008; 34(2):208–14. https://doi.org/10.1016/j.jsat.2007.03.009 PMID: 17596905

22. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005; 43(11):1130–9. https://doi.org/10.1097/01.mlr.0000182534.19832.83 PMID: 16224307

23. Charlson ME, Pompei P, Ales KL, Mackenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40(5):373–83. https://doi.org/10.1016/0021-9681(87)90129-5 PMID: 7722560

24. Akaike H. A new look at statistical model identification. IEEE Transactions on Automatic Control. 1974; 6:716–23.

25. Schwarz G. Estimating the dimension of a model. Annals of Statistics. 1978; 6:461–4.

26. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994; 47(11):1245–51. https://doi.org/10.1016/0895-4356(94)90129-5 PMID: 7722560

27. Pisanu C, Franconi F, Gessa GL, Mameli S, Pisanu GM, Campesi I, et al. Sex differences in the response to opioids for pain relief: A systematic review and meta-analysis. Pharmacol Res. 2019; 148:104447. https://doi.org/10.1016/j.phrs.2019.104447 PMID: 31499196

28. Serradurevic M, Striley CW, Cottler LB. Sex differences in prescription opioid use. Curr Opin Psychiatry. 2017; 30(4):238–46. https://doi.org/10.1097/YCO.0000000000000337 PMID: 28426545

29. Hirschtritt ME, Delucchi KL, Olff M. Outpatient, combined use of opioid and benzodiazepine medications in the United States, 1993–2014. Prev Med Rep. 2018; 9:49–54. https://doi.org/10.1016/j.pmedr.2017.12.016 PMID: 29340270

30. Serradurevic M, Striley CW, Gurka KK, Leeman RF, Cottler LB. Sex differences in prescription opioid use patterns assessed through a community engagement program in Florida. Drug Alcohol Depend. 2019; 204:107568. https://doi.org/10.1016/j.drugalcdep.2019.107568 PMID: 31568932

31. Silver ER, Hur C. Gender differences in prescription opioid use and misuse: Implications for men’s health and the opioid epidemic. Prev Med. 2020; 131:105946. https://doi.org/10.1016/j.ypmed.2019.105946 PMID: 31816359

32. Colliver JD, Grofner JC. Motive for nonmedical use of prescription pain relievers in the National Survey on Drug Use and Health. J Pain. 2008; 9(6):487–9; discussion 94–6. https://doi.org/10.1016/j.jpain.2008.03.001 PMID: 18403270

33. Back SE, Payne RL, Simpson AN, Brady KT. Gender and prescription opioids: findings from the National Survey on Drug Use and Health. Addict Behav. 2010; 35(11):1001–7. https://doi.org/10.1016/j.addbeh.2010.06.018 PMID: 20598809
34. Williams JR, Girdler S, Williams W, Cromeens MG. The effects of co-occurring interpersonal trauma and gender on opioid use and misuse. J Interpers Violence. 2021; 36(23–24):NP13185–NP205. https://doi.org/10.1177/0886260519000309 PMID: 32054388

35. Ly DP. Racial and ethnic disparities in the evaluation and management of pain in the outpatient setting, 2006–2015. Pain Med. 2019; 20(2):223–32. https://doi.org/10.1093/pmy/074 PMID: 29688509

36. Singhal A, Tien YY, Hsaia RY. Racial-ethnic disparities in opioid prescriptions at emergency department visits for conditions commonly associated with prescription drug abuse. PLoS One. 2016; 11(8): e0159224. https://doi.org/10.1371/journal.pone.0159224 PMID: 27501459

37. Lee P, Le Saux M, Siegel R, Goyal M, Chen C, Ma Y, et al. Racial and ethnic disparities in the management of acute pain in US emergency departments: Meta-analysis and systematic review. Am J Emerg Med. 2019; 37(9):1770–7. https://doi.org/10.1016/j.ajem.2019.06.014 PMID: 31186154

38. Morales ME, Yong RJ. Racial and Ethnic Disparities in the Treatment of Chronic Pain. Pain Med. 2021; 22(1):75–90. https://doi.org/10.1093/pm/pnaa427 PMID: 33367911

39. Moskowitz D, Thom DH, Guzman D, Penko J, Miaszkowski C, Kushel M. Is primary care providers’ trust in socially marginalized patients affected by race? J Gen Intern Med. 2011; 26(8):846–51. https://doi.org/10.1007/s11606-011-1672-2 PMID: 21394422

40. Burgess DJ. Addressing racial healthcare disparities: How can we shift the focus from patients to providers? J Gen Intern Med. 2011; 26(6):553–8. https://doi.org/10.1007/s11606-011-1748-z PMID: 21647749

41. Pascoe EA, Smart Richlan M. Perceived discrimination and health: A meta-analytic review. Psychol Bull. 2009; 135(4):531–54. https://doi.org/10.1037/a0016059 PMID: 19586161

42. Blanchard J, Lurie N. R-E-S-P-E-C-T: patient reports of disrespect in the health care setting and its impact on care. J Fam Pract. 2004; 53(9):721–30. PMID: 15353162

43. Trivedi AN, Ayanian JZ. Perceived discrimination and use of preventive health services. J Gen Intern Med. 2006; 21(6):553–8. https://doi.org/10.1111/j.1525-1497.2006.00413.x PMID: 16808735

44. Shavers VL, Fagan P, Jones D, Klein WM, Boyington J, Moten C, et al. The state of research on racial/ethnic discrimination in the receipt of health care. Am J Public Health. 2012; 102(5):953–66. https://doi.org/10.2105/AJPH.2012.300773 PMID: 23494002

45. Robinson L, Spilsbury K. Systematic review of the perceptions and experiences of accessing health services by adult victims of domestic violence. Health & social care in the community. 2008; 16(1):16–30. https://doi.org/10.1111/j.1365-2605.2007.00721.x PMID: 18181812

46. Chang JC, Decker MR, Moracco KE, Martin SL, Petersen R, Frasier PY. Asking about intimate partner violence: advice from female survivors to health care providers. Patient education and counseling. 2005; 59(2):141–7. https://doi.org/10.1016/j.pec.2004.10.008 PMID: 16257618

47. Williams JR, Gonzalez-Guarda RM, Halstead V, Martinez J, Joseph L. Disclosing gender-based violence during health care visits: A patient-centered approach. J Interpers Violence. 2020; 35(23–24):5552–73. https://doi.org/10.1177/0886260517720733 PMID: 29294854

48. Lagdon S, Armour C, Stringer M. Adult experience of mental health outcomes as a result of intimate partner violence victimization: A systematic review. Eur J Psychiatry. 2014; 5:24794.

49. Konkoly Thege B, Horwood L, Slater L, Tan MC, Hodgins DC, Wild TC. Relations hip between interper-
55. Substance Abuse and Mental Health Services Administration. Trauma-informed care in behavioral health services. Treatment Improvement Protocol (TIP) Series 57. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2014. Report No.: HHS Publication No. (SMA) 13–4801.

56. Purtle J. Systematic Review of Evaluations of Trauma-Informed Organizational Interventions That Include Staff Trainings. Trauma Violence Abuse. 2020; 21(4):725–40. https://doi.org/10.1177/1524838018791304 PMID: 30079827

57. Machtinger EL, Cuca YP, Khanna N, Rose CD, Kimberg LS. From treatment to healing: the promise of trauma-informed primary care. Women’s Health Issues. 2015; 25(3):193–7. https://doi.org/10.1016/j.who.2015.03.008 PMID: 25965151

58. Williams JR, Gonzalez-Guarda R, Ilias V. Trauma-informed decision-making among providers and victims of intimate partner violence during HIV testing: A qualitative study. The Journal of the Association of Nurses in AIDS Care: JANAC. 2017. https://doi.org/10.1016/j.jana.2017.03.008 PMID: 28526332

59. Baird C. A Trauma-Informed Approach to Substance Abuse Treatment. J Addict Nurs. 2018; 29(4):262–3. https://doi.org/10.1097/JAN.0000000000000251 PMID: 30507823

60. Marsac ML, Kassam-Adams N, Hildenbrand AK, Nicholls E, Winston FK, Leff SS, et al. Implementing a Trauma-Informed Approach in Pediatric Health Care Networks. JAMA Pediatr. 2016; 170(1):70–7. https://doi.org/10.1001/jamapediatrics.2015.2206 PMID: 26571032

61. Moloney B, Cameron I, Baker A, Feeney J, Korner A, Kornhaber R, et al. Implementing a Trauma-Informed Model of Care in a Community Acute Mental Health Team. Issues in mental health nursing. 2018; 39(7):547–53. https://doi.org/10.1080/01612840.2018.1437855 PMID: 29648912

62. Loomis B, Epstein K, Dauria EF, Dolce L. Implementing a Trauma-Informed Public Health System in San Francisco, California. Health Educ Behav. 2019; 46(2):251–9. https://doi.org/10.1177/1090198118806942 PMID: 30336689